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Abstract
Background: Mycophenolic acid (MPA) is an immunosup-
pressant for which therapeutic drug monitoring (TDM) is
performed for optimal prophylaxis and avoidance of toxicity
in transplant patients. Liquid chromatography-tandem mass
spectrometry (LC-MS/MS) is ideally suited for TDM of
MPA. There have been several method comparisons of the
Roche Total MPA assay, but none have been performed with
respect to liver transplant patients.
Methods: We validated the Roche Total MPA assay on the
Cobas Integra 400 and Cobas 6000 and compared it to a
validated LC-MS/MS (API 2000) method. Fifty-five
EDTA plasma samples from liver transplant patients were
measured with the Roche assay on these platforms and com-
pared to the LC-MS/MS results.
Results: Validation of the LC-MS/MS, Cobas Integra 400
and 6000 was performed with good results. The LC-MS/MS/
Integra 400/Cobas 6000 were linear up to 30, 15 and 17
mg/L, respectively. Imprecision was -10% for LC-MS/MS
and -7% for the Roche assay on both platforms. The sam-
ples showed good agreement with LC-MS/MS. Passing-
Bablok regression analysis showed Cobas Integra (mg/L)s
1.02=LC-MS/MS (mg/L)–0.50 and Cobas 6000 (mg/L)s
0.98=LC-MS/MS–0.47.
Conclusions: The Roche Total Mycophenolic Acid-assay is
suitable for measuring total MPA in plasma from liver trans-
plant patients and is a good alternative for LC-MS/MS.
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Introduction
In transplant patients, mycophenolic acid (MPA) has a prom-
inent role in the prophylaxis of acute rejection. The drug is
administered to kidney, heart, liver, lung, bowel, pancreas
and bone marrow transplant patients. MPA is commonly used
in combination with corticosteroids and calcineurin inhibi-
tors, such as tacrolimus and cyclosporine, or in combination
with the macrolide antibiotic sirolimus (1).
Two forms are widely available: the prodrug mycophe-
nolate mofetil (MMF) and the enteric-coated mycophenolate
sodium (EC-MPS). MMF and EC-MPS are absorbed from
the gastrointestinal tract and hydrolyzed, resulting in a high
MPA bioavailability ()90%). MPA is the active metabolite
of MMF. MPA is metabolized in the liver to the pharmaco-
logically inactive phenolic glucuronide (MPAG), a phenolic
glucoside and the in vitro active acyl glucuronide (AcMPAG)
(2, 3). The pharmacokinetics of MPA are complicated by the
enterohepatic circulation, giving rise to a second peak of
MPA 6–12 h following oral administration. Furthermore, the
pharmacokinetics are influenced by the high protein binding
of MPA; 97% of MPA is bound to plasma albumin and only
the free fraction has immunosuppressive action (4). Thera-
peutic drug monitoring (TDM) of MPA may minimize the
risk for rejection after transplantation. Despite insufficient
evidence to provide unequivocal guidelines on the require-
ment for MPA monitoring in liver transplantation, the latest
Consensus Report indicated six conditions where TDM
of MPA is recommended (1). Monitoring the area under
the curve (AUC) has been recommended, an AUC0–12 h
)30 mg/L/h and -60 mg/L/h provides optimal prophylaxis
(1, 5).
The standard procedures to quantify MPA currently used
are high performance liquid chromatography (HPLC) and
liquid chromatography-tandem mass spectrometry (LC-MS/
MS). The use of the Enzyme Multiplied Immunoassay Tech-
nique (EMIT) and Cloned Enzyme Donor Immunoassay
method (CEDIA) for MPA have not gained widespread use,
mainly because of the cross-reactivity with the metabolite
AcMPAG (6–12). The use of the Roche Total Mycophenolic
Acid assay has previously been compared with HPLC and
LC-MS/MS methods for renal and cardiac transplant patients
(13–16). However, to our knowledge there have been no
studies about the performance in liver transplant patients. In
this study, we evaluated the Roche Total Mycophenolic
Acid assay (Roche Diagnostics, IN, USA) on the COBAS
Integra 400 and Cobas 6000 (Roche Diagnostics, IN,
USA) and compared it with LC-MS/MS.
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Figure 1 Schematic overview of the enzymatic reaction of the
Roche Total Mycophenolic Acid assay.
IMP, inosine monophosphate; NAD, nicotinamide adenine dinucleo-
tide; MPA, mycophenolic acid; IMPDH-II, type 2 inosine mono-
phosphate dehydrogenase; XMP, xanthosine monophosphate. IMP
is enzymatically converted into XMP through the enzyme IMPDH-
II. This step requires conversion of NAD to NADH. MPA blocks
the enzymatic process of IMP into XMP. When MPA is present,
there is no formation of XMP and hence no release of NADH. In
the assay from Roche, the formation of NADH is measured at
340 nm. NADH production is inversely proportional to the concen-
tration of MPA.
Materials and methods
Sample collection
Fifty-five EDTA plasma samples from liver transplant patients at
our university hospital were collected. These samples were analyzed
on the three platforms on the same day. The samples were anony-
mized leftover samples from routine analysis.
Enzyme assay
The Roche Total Mycophenolic Acid assay was performed on the
Cobas Integra 400 and Cobas 6000 (Roche Diagnostics, IN,
USA) according to the manufacturer’s instructions. Reactions con-
ditions are detailed in Figure 1. We used serum-based total MPA
calibrators and total MPA controls from Roche Diagnostics for all
assays. The calibrators consisted of six levels: 0, 1, 3, 5, 10 and
15 mg/L. The controls consisted of three levels: 0.869 mg/L (range
0.695–1.043 mg/L), 3.58 mg/L (range 2.86–4.30 mg/L) and
12.5 mg/L (range 10.1–14.9 mg/L).
LC-MS/MS
LC-MS/MS was performed with an API 2000 (Applied Biosys-
tems, Foster City, CA, USA) with an electrospray ionization (ESI)
inlet. The mobile phase was a gradient of 2 mmol/L ammonium
acetate (Fluka, Buchs, Switzerland) in water and methanol (Bio-
solve BV, Valkenswaard, The Netherlands). The column used was
an Agilent Zorbax RP-C18, 2.1=30 mm (Agilent Technologies
Inc., Santa Clara, CA, USA). Precipitation fluid (200 mL) contain-
ing 3.33 mg/L internal standard mycophenolic acid carboxyether
(Roche Bioscience, Palo Alto, CA, USA) in methanol (Biosolve BV,
Valkenswaard, The Netherlands) and zinc sulphate 0.3 mol/L
(Merck nv, Overijse, Belgium) (70/30 vol:vol) was added to the
EDTA plasma samples (50 mL). After vortexing for 1 min, 5 min
centrifugation at 12,000 rpm, the supernatant (60 mL) was trans-
ferred into a vial. The injection volume was 3 mL. The system
consisted of an Agilent 1100 LC Quaternary Pump, thermostated
to 408C by an Agilent Column Oven. During the acquisition there
was a flow rate of 500 mL/min using solvent A (2 mmol/L NH4q
in water) and solvent B (2 mmol/L NH4q in methanol). An eluent
gradient was used, starting with 1.5 min 90% A and 10% B, 9.5 min
5% A and 95% B and ending with 12 min 90% A and 10% B. We
used a multiple reaction monitoring (MRM) acquisition method of
12 min. The following transitions were monitored: 438.3/303.0
(NH4q-MPAC), 421.1/303.2 (MPAC), 338.2/207.0 (NH4q-MPA,
quantifier transition), 321.1/303.1 (MPA) and 321.1/159.0 (qualifier
transition). The ammonium adduct of MPA and MPAC was used
for sample quantification.
Statistical analysis
We used MedCalc (MedCalc Software, Mariakerke, Belgium) and
Microsoft Office Excel (Microsoft Corporation, Redmond, WA,
USA). A Grubbs test, a one sided F-test and a one-way ANOVA
test were used in the LC-MS/MS method validation. Passing-Bablok
regression analysis was performed in the method comparison.
LC-MS/MS method validation
The LC-MS/MS method for the quantification of total mycophe-
nolate (tMPA) in plasma, was validated according to a published
experimental design (17). This design includes a pre-validation and
a main validation phase.
In the pre-validation phase, absence of interferences (selectivity),
matrix effects, processed sample stability and linearity were inves-
tigated. Ion suppression/enhancement (ME), extraction efficiency
(RE) and process efficiency (PE) were measured as described by
Matuszewski et al. (18). Linearity was assessed after removing out-
liers with the Grubbs test (19), and the check for homogeneity of
variance was performed with a one-sided F-test between the vari-
ances at the highest and lowest concentration values (17). A p-value
-0.05 was considered significant.
For the main validation, the Roche total MPA calibrators and
control material were run over an 8 day period in duplicate, with a
new calibration curve obtained each day. Using a one-way ANOVA
with each day as the grouping variable allowed the calculation of
intra- and inter-assay precision, and total assay precision expressed
as percent coefficient of variation (CV) (17). In order to measure
the variability of the calibration curve, the imprecision and accuracy
characteristics were determined, as well as the lower limit of quan-
tification (LLOQ). The imprecision and accuracy was deemed
acceptable, at respectively, 10% and 15%, and the CV and bias at
LLOQ at 20% (20). The dilution experiment was performed with a
serial dilution (dilution 2, 4, 8) with bovine serum on a spiked
plasma pool (60 mg/L). The plasma pools underwent three freeze/
thaw cycles.
Method validation on Cobas Integra 400 and Cobas
6000
In order to assess linearity, 11 dilutions were made spanning
0%–100% of a high concentration pool (28.5 mg/L). The lower
limit of detection (LLOD) was measured by running 21 replicates
of three blank samples on three different days. The LLOQ was
determined using a functional sensitivity approach. Ten aliquots of
five patient samples with total MPA concentrations between 0.45
and 0.85 mg/L were analyzed on 10 different days. Imprecision
characteristics were determined by analyzing the Roche total MPA
controls, Roche total MPA calibrator B (1 mg/L) and three total
MPA plasma pools (0.8, 2.5 and 9.0 mg/L), in triplicate for 21 days.
The criteria from Roche Diagnostics were used to evaluate the
imprecision: SDF0.07 up to a concentration of 1 mg/L and CV
F7.0% at concentrations )1 mg/L.
Method comparison
Only measurements up to 15 mg/L could be used for comparison
because the Cobas Integra reports all results )15 mg/L as
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Table 1 Imprecision and accuracy characteristics of the LC-MS/MS method. Quality control materials were run over 8 days in duplicate
(a and b).
Low Medium High
QCIa QCIb QCIIa QCIIb QCIIIa QCIIIb
Target, mg/mL 0.87 0.87 3.58 3.58 12.50 12.50
Mean, mg/mL (ns8) 0.84 0.86 3.50 3.64 12.26 12.59
Bias, % –4.0 –0.5 –2.2 1.8 –1.9 0.7
Intra-assay CV, % 3.5 5.5 3.1
Inter-assay CV, % 2.9 0.0 0.0
Total precision CV, % 4.6 5.3 2.7
SD, standard deviation; CV, coefficient of variation.
‘)15 mg/L’. Higher concentrations can be diluted with blank plas-
ma or diluent, but we did not evaluate this. Forty-seven of 55 sam-
ples were -15 mg/L, the other eight samples were excluded from
the method comparison.
For evaluating the degree of agreement, Passing-Bablok regres-
sion analysis was used to determine proportional and constant bias
by checking of the 95% confidence intervals (CI) of the slope and
the intercept. If one was not included in the 95% CI of the slope,
there is constant error, and if zero was not included in the 95% CI
of the intercept, proportional error is present.
Results
LC-MS/MS method validation
Pre-validation No interferences were detected with 10 dif-
ferent blank plasma samples and two zero samples. Possible
interference from cyclosporine, tacrolimus, sirolimus and
everolimus was tested at concentrations of, respectively, 514,
16.7, 20.4 and 8.48 mg/L. The compounds did not cause any
interference.
The ME, RE and PE were, respectively, 87%, 97% and
85% for the low concentration, and 85%, 98% and 83% for
the high concentration. Our method showed similar results
as Shen et al. (ME 90.7%–94.3%; RE 90.6%–93.4%) (21).
There were no obvious changes in stability of processed
samples during the analysis. The within-group CV at
0.63 mg/L was 5.2%, and at 3.14 mg/L was 4.4%. Ranging
from 0 to 30 mg/L, the linearity was determined after iden-
tifying one outlier and performing a one-sided F-test between
the variances at the 6 mg/L pool and the 30 mg/L pool. The
variance ratio was 2.36 (ps0.363), the variance over the
calibration range is not homogeneous and therefore a weighted
regression model was used (weighting factor 1/x, rs0.99).
Main validation Variability of the calibration curve: two
concentration levels in our six-point calibration curve were
too high. The target concentrations of 1 mg/L and 5 mg/L
were not within the 95% confidence interval of our measured
mean value, respectively w1.0068–1.0832x and w5.0073–
5.2802x. The blank calibrator was excluded from this exper-
iment, the other five concentration levels were: 1, 3, 5, 10,
15 mg/L, and the between run CVs were respectively: 4.4,
2.6, 3.2, 2.9, 1.9%. The within group CV was 1.6%. Bias
ranged from 0.04% to 4.5%.
Results of accuracy and imprecision are given in Table 1.
At each QC level, the CV and bias was -10%. The LLOQ
was determined by analyzing two spiked plasma pools at two
different concentrations (0.18–0.36 mg/L). The criterion of
-20% CV was met for both concentrations. The LLOQ was
therefore set to 0.18 mg/L.
The within group CV at dilution 1 (60 mg//L), 2 (30 mg/L),
4 (15 mg/L), 8 (7.5 mg/L) were respectively 6.3%, 8.8%,
6.2%, 8.4%. Linearity was good up to 30 mg/L. Above this
concentration, the test reached a plateau, with a high negative
bias (19%) at 60 mg/L. The 24 results at each concentration
all gave -10% CV.
Method validation on Cobas Integra 400 and Cobas
6000
The linearity could only be measured partially on the Cobas
Integra 400, where all results )15 mg/L are expressed as
‘)15’. The bias was -10% for all measured concentrations
and linearity was good between 0.4 and 15 mg/L. On the
Cobas 6000 the method was not linear up to 28.5 mg/L, but
up to 17 mg/L only. Analyzing blank samples on the Cobas
Integra yielded an LLOD that was -0.4 mg/L. On the Cobas
6000, all results were lower than the LLOQ (0.45 mg/L) with
a mean LLOD of 0.06 mg/L. The functional sensitivity was
evaluated using five samples with mean concentrations rang-
ing from 0.45 to 0.85 mg/L, the CV for the Cobas Integra
ranged between 5.3% and 12.8% and for the Cobas 6000
between 5.1% and 13.8%. The LLOQ was 0.45 mg/L for the
Cobas Integra and 0.48 mg/L for the Cobas 6000.
The Cobas Integra and the Cobas 6000 met the Roche
imprecision criteria for all levels, except for calibrator B on
the Cobas 6000 (SDs0.13). There were no significant dif-
ferences in CV or bias between Cobas Integra 400 and Cobas
6000.
Method comparison
Figures 2 and 3 show good the agreement between LC-MS/
MS and the Cobas Integra 400 and Cobas 6000. The range
of measurement was 1.19–14 mg/L (median, 5.35 mg/L) for
LC-MS/MS, 0.72–14.68 mg/L (median, 5.02 mg/L) for Inte-
gra and 0.63–14.16 mg/L (median, 4.89 mg/L) for Cobas
6000. Passing-Bablok regression analysis yielded an equation
of Cobas Integra 400 (mg/L)s1.02=LC-MS/MS (mg/L)
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Figure 2 Passing-Bablok regression analysis of the Cobas Integra
400 with LC-MS/MS.
Cobas Integra 400 (mg/L)s1.02=LC-MS/MS (mg/L)–0.50
(r2s0.98). The full line is the regression-line. The two dashed lines
show the 95% confidence interval and the point line is slopes1.
Figure 3 Passing-Bablok regression analysis of Cobas 6000 with
LC-MS/MS.
Cobas 6000 (mg/L)s0.98=LC-MS/MS (mg/L)–0.47 (r2s0.98).
The full line is the regression-line. The two dashed lines show the
95% confidence interval and the point line is slopes1.
Figure 4 Bland-Altman plot of the Cobas Integra compared to
LC-MS/MS.
The Bland-Altman plot of the Cobas Integra compared to LC-MS/
MS demonstrates that Cobas Integra 400 measures approximately
0.26 mg/L lower than LC-MS/MS. The two point-dashed lines are
the 95% confidence interval of mean of differences. The point line
is the line of equality.
Figure 5 Bland-Altman plot of the Cobas 6000 compared to
LC-MS/MS.
Bland-Altman plot of the Cobas 6000 compared to LC-MS/MS
demonstrates that the Cobas 6000 measures approximately 0.45
mg/L lower than LC-MS/MS. The two point-dashed lines are the
95% confidence interval of mean of differences. The point line is
the line of equality.
–0.50 (95% CI intercept: –0.66 to –0.281; 95% CI slope:
0.96–1.03) (Figure 2) and Cobas 6000 (mg/L)s0.98=LC-
MS/MS (mg/L)–0.47 (95% CI intercept: –0.72 to –0.324;
95% CI slope: 0.99–1.06) (Figure 3). The mean absolute
difference was, respectively, 0.45 mg/L and 0.26 mg/L (Fig-
ures 4 and 5). These results indicate that there is constant
error, but no proportional error.
Discussion
There is a good agreement between results of the LC-MS/
MS and Cobas Integra or Cobas 6000. As indicated in Table
2, our regression analysis is similar to other studies (13–15,
22, 23). However, in our study, a higher intercept was
obtained. The intercepts of the Cobas Integra 400 (–0.50)
and the Cobas 6000 (–0.47) were similar. Problems with LC-
MS/MS, such as falsely lowered results due to ion suppres-
sion, or falsely elevated results by in-source fragmentation
of the phenolic glucuronide have been described (24). The
Bland-Altman plots in Figures 4 and 5 indicate that the enzy-
matic assays yield lower results than the LC-MS/MS, for the
Cobas 6000 approximately 0.45 mg/L and the Cobas Integra
0.26 mg/L. However, the observed percent ion suppression
(14%) in our study could not explain the lower intercept, and
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Table 2 Summary of published method comparison studies between measurement of total MPA with the enzymatic assay and chromato-
graphic methods.
Author Year Group specifications n Linear regression Correlation Reference Analyzer
method
Domke et al. (22) 2005 Total MPA 96 1.061xq0.11 rs0.99 LC-MS/MS Cobas Integra
(abstract)
Marquet et al. 2006 Adult renalqtacrolimus 270 1.044xq0.03 r2s0.97 LC-MS/MS Cobas Integra
(14) (abstract) Adult lungqtacrolimus 109 1.025xq0.059 r2s0.96 LC-MS/MS Cobas Integra
Adult renalqsirolimus 240 1.105x–0.144 r2s0.97 LC-MS/MS Cobas Integra
Pediatric renalqcyclosporin 115 1.0xq0.06 r2s0.96 LC-MS/MS Cobas Integra
Adult renalqcyclosporin 119 1.208x–0.109 r2s0.98 LC-MS/MS Cobas Integra
Luthe et al. 2006 Renal/cardiac transplant 87 1.055x–0.010 rs0.98 LC-MS/MS Cobas Integra 800
(23) (poster) Renal/cardiac transplant 87 1.045xq0.1011 rs0.97 LC-MS/MS Cobas C501
Renal/cardiac transplant 65 1.12xq0.009 rs0.98 LC-MS/MS Cobas Integra 400
Brandhorst et al. 2008 Renal transplant 174 1.09x–0.13 rs0.99 HPLC-UV Cobas Integra 800
(13) – 87 1.06x–0.01 rs0.98 LC-MS/MS Cobas Integra 800
Renal transplant 190 1.01xq0.04 rs0.99 LC-MS/MS Cobas C501
Renal transplant 65 1.12xq0.01 rs0.98 LC-MS/MS Cobas Integra 400
Renal/cardiac transplant 265 1.01xq0.06 rs0.99 HPLC-UV Cobas Integra 400
Renal/cardiac transplant 60 1.17x–0.17 rs0.98 HPLC-UV Cobas Integra 400
Tacrolimus 158 1.01xq0.08 rs0.99 – –
Cyclosporine 32 0.99xq0.01 rs1.00 – –
Van Gelder et al. 2009 Renal transplant 1986 1.009x–0.05 rs0.99 LC-MS/MS Cobas Integra 800
(16) Cyclosporine 242 1.037x–1.046 rs0.99 LC-MS/MS Cobas Integra 800
Tacrolimus 462 1.020x–0.626 rs0.99 LC-MS/MS Cobas Integra 800
Marquet et al. 2009 Renal transplant 694 1.079x–0.031 rs0.98 LC-MS/MS Cobas Integra 400
(15) Lung transplant 109 1.045xq0.048 rs0.99 LC-MS/MS Cobas Integra 400
Linear regression: y, Roche Total MPA assay on mentioned automatic platforms; x, LC-MS/MS or HPLC-UV. Cobas C501, Cobas 6000.
the in-source fragmentation of the phenolic glucuronide was
not present in our method. Moreover, MPA and MPAG were
baseline separated. Besides this constant error, the slopes and
coefficients of the regression analysis were comparable with
other studies. Together with other studies, summarized in
Table 2, there is sufficient proof that the Roche assay can
quantitatively measure total MPA in liver transplant patients.
However, further studies are needed to confirm the negative
bias.
A well described problem for the EMIT and CEDIA meth-
od is the overestimation of, respectively, 25% and 36% of
the MPA concentration at the LLOQ concentration. This
could partly be explained by cross-reactivity with AcMPAG
(1). For the IMPDH (type 2 inosine monophosphate dehy-
drogenase)-based enzyme inhibition enzyme assays (Roche),
MPA overestimation by AcMPAG was low (-5%) and was
considered as clinically irrelevant (13). In our study, too few
samples at such concentrations were included in the study to
confirm these findings.
The most important advantage of chromatography is the
possibility to measure the MPA metabolites. Measurement of
the metabolites is a growing concern, especially in liver and
renal compromised patients. The largest CVs for AUC and
predose concentrations were found in postoperative liver
transplant patients and in renal transplant patients with early
graft dysfunction. For liver transplant patients this is proba-
bly due to hyperbilirubinemia, uremia and hypoalbuminemia.
MPA is 97% bound to albumin, while MPAG is only 82%
bound to albumin. MPAG itself is not pharmacologically
active, the formation of an O- or N-glucuronides is a com-
mon pathway in phase II drug metabolism and is considered
a detoxification mechanism (25). However, high MPAG con-
centrations can augment the free fraction of MPA by dis-
placement effects on albumin (26). In case of liver transplant
patients, measuring high MPAG can indicate an increase in
free MPA. Renal insufficiency is characterized by a higher
free MPA fraction and lower total MPA due to restrictive
clearance (27). Besides the need for measuring both MPA
and MPAG, AcMPAG should also be measured. The immu-
nosuppressant action of MPA is an uncompetitive and revers-
ible inhibition of IMPDH, resulting in a decreased de novo
synthesis of guanine nucleotides and impaired nucleic acid
synthesis (25). AcMPAG seems to inhibit IMPDH in vitro,
but its possible immunosuppressive activity needs to be fur-
ther investigated. In contrast, AcMPAG may be involved in
the development of gastrointestinal side-effects associated
with MPA. Wieland et al. demonstrated in vitro that an acyl
glucuronide has the potential to induce a proinflammatory
reaction in human leukocytes. As diarrhea and intestinal
ulceration may result from an inflammatory reaction, and
AcMPAG would promote release of cytokines in vivo,
AcMPAG could contribute to these toxic actions of MPA (2,
25). Many chromatographic methods to measure free MPA,
MPAG and AcMPAG have been described (21, 26, 28–33).
The downside is that they all require a significant amount of
knowledge, sophisticated equipment and trained technicians,
and are therefore expensive and time-consuming.
The latest consensus report on TDM of MPA advises
measurement of total MPA in limited sampling strategies for
solid organ transplants. Measuring free MPA or metabolites
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of MPA is so far not included in the consensus report (1).
Concentration-controlled MPA dosing is only needed for
patients who are at immunologic risk, patients with altered
renal, hepatic or bowel function and patients undergoing
minimization or withdrawal of therapy. However, there is
still no evidence that TDM of MPA provides benefit in graft
outcome or patient survival (1).
In conclusion, the Roche assay is a good alternative for
LC-MS/MS or HPLC-UV method if total MPA dosing is
sufficient. The observed constant bias of 0.5 mg/L needs to
be confirmed in further studies. We confirmed that the total
MPA assay of Roche performs as well as LC-MS/MS, and
is therefore a reliable method to measure total MPA in liver
transplant patients.
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